返回排名列表

Elevance Health Inc (ELV)

合理估值
HealthcareHealthcare PlansUnited States

基本面

71

价格

$383.37

市值

$85.57B

第一部分 · 这家公司值多少

概览

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

P/E: 23.6Score: 70Market cap: $336.61B

The largest US health insurer, bidding against Elevance for the same employer contracts, Medicare Advantage members and state Medicaid programs, and pairing insurance with health services just as Elevance does with Carelon.

P/E: 22.6Score: 58Market cap: $112.36B

Through Aetna it sells commercial, Medicare Advantage and Medicaid plans in the same states as Elevance, and its pharmacy benefit arm competes for the same drug-benefit spending.

P/E: —Score: 53Market cap: $30.89B

The biggest Medicaid managed-care company in the country and Elevance's main rival in state Medicaid procurements and on the Affordable Care Act exchanges.

P/E: 11.2Score: 70Market cap: $71.83B

Competes head-on for large national and multi-state employer accounts, the segment where Elevance's Blue Cross Blue Shield network is its main selling point.

P/E: 40.7Score: 62Market cap: $46.78B

Concentrated on Medicare Advantage, where it competes for the same over-65 members Elevance is courting as its fastest-growing business.

Molina Healthcare, Inc.MOH

A pure-play government-programs insurer that bids against Elevance for the same state Medicaid and dual-eligible contracts.

资产负债表与流动性

营收

$199.13B

截至2025/12/31的财政年度

净利润

$5.66B

截至2025/12/31的财政年度

自由现金流

$3.17B

股东权益合计

$43.88B

负债合计

$77.47B

流动比率

1.52

利息覆盖率

5.13

债务/EBITDA

3.55

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形合理估值

公允价值

$497.22

当前价格

$383.37

安全边际

+22.9%

公允价值区间

$323.19 - $671.25

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$451.38
现金流折现法(DCF):$1058.45
市盈率法(P/E):$315.56
格雷厄姆成长公式:$447.48
盈利能力价值(EPV):$327.00
合理市净率(P/B):$351.57
股息折现模型(戈登模型):$173.31
P/FFO(运营资金):$531.79
周期中段收益:$1031.71
市销率法(P/S):$3636.37
分析师共识:买入 (19B / 10H / 0S)
最近财报超预期:+18.85%

估值指标

市盈率(P/E)

15.65

ROE

12.9%

市净率(P/B)

1.88

P/FCF

13.41

毛利率

89.4%

ROIC

7.1%

盈利能力雷达图

价值创造(经济护城河)

ROIC

7.1%

WACC

6.9%

ROIC − WACC

+0.2 pp

ROIC 与资本成本大致持平:公司仅仅覆盖了资本成本。

基本面分析标准

通过(21)

  • EPS shows upward trend
  • EPS CAGR 8.76%
  • Price CAGR 11.28%
  • ROIC 7.1%
  • Gross Margin 89.4%
  • P/FCF 13.41
  • P/B Ratio 1.88
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 11.2%
  • Revenue Growth 5Y 10.3%
  • Analyst Consensus 66% Buy
  • Earnings Surprise avg 15.4%
  • Earnings Quality (OCF/NI) 0.76
  • Share Dilution -3.6%
  • Piotroski F-Score 7/9

未通过(5)

  • Operating Margin 3.6%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 2.47

不可用(2)

  • Dividend Payout NaN%
  • Net Margin Trend (invalid data)

Piotroski F-评分

7/9

财务状况强健

score
criteria

盈利质量

0.76

中等:利润与现金之间存在一定差距

股权稀释

-3.6%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Ms. Gail Koziara BoudreauxPresident, CEO & Director64
Mr. Mark Bradley KayeExecutive VP & CFO45
Mr. Peter David Haytaian Esq.Special Advisor55
Mr. Charles Morgan Kendrick Jr.EVP and President of Commercial & Specialty Health Benefits59
Ms. Felicia Farr NorwoodExecutive VP & Chief Health Benefits Officer65
Mr. Scott Wayne AnglinSVP, Treasurer & Chief Investment Officer-
Mr. Ronald William PenczekSenior VP, Controller & Chief Accounting Officer60
Mr. Nathan Allen RichVice President of Investor Relations-
Ms. Erin M. WesslingExecutive VP & Chief Legal Officer47
Ms. Julie GoonSenior Vice President of Public Affairs-

审计风险

1

董事会风险

1

薪酬风险

2

股东权利风险

6

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-06

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-07-15

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-09-10

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for ELV, sourced from Markets Gazette.

  • 4/22/2026POSITIVE
    Elevance Health Earnings And Guidance Hike Offset Cost Concerns

    Elevance Health exceeded first-quarter earnings expectations, reporting $6.05 per share against a consensus of $5.70, a 6.1% beat. The company also raised its full-year 2026 outlook, projecting adjusted earnings per share between $18.40 and $18.80, up from the previous guidance of $18.20 to $18.60. This upward revision, coupled with steady revenue growth, suggests strong operational performance. However, investors should note the company flagged increased cost pressures in its Medicaid business and a significant accrual related to CMS rates, which could impact future profitability.

  • 4/7/2026POSITIVE
    Elevance Health Stock Soars After 2.48% Medicare Rate Increase

    Elevance Health Inc. experienced a significant surge on Tuesday following the finalization of a substantial 2.48% increase in Medicare Advantage reimbursement rates for 2027 by federal regulators. This favorable adjustment is expected to directly boost the company's revenue streams from its government-backed health insurance plans. For investors, this news signals improved profitability prospects and a more robust financial outlook for Elevance Health, potentially leading to upward price target revisions and increased institutional interest.

  • 3/2/2026NEGATIVE
    Elevance Health Stock Sinks After CMS Freezes Medicare Advantage Enrollment

    Markets Gazette reports a significant decline in Elevance Health's stock value following the Centers for Medicare & Medicaid Services (CMS) decision to freeze new enrollments in its Medicare Advantage program. The CMS action stems from serious compliance concerns dating back to 2018. This halt in new admissions represents a substantial blow to Elevance Health, as the Medicare Advantage program is a critical component of its business and future growth strategy. Investors reacted sharply, driving the stock price down, reflecting uncertainty about the long-term financial impact of these restrictions and the company's reputation. The situation demands careful management from the company's leadership to restore regulatory and market confidence.

  • 2/25/2026POSITIVE
    After stints at Nike and Kohl’s, Elevance Health’s CDIO pivots to using tech to bring more ‘delight’ to healthcare

    Ratnakar Lavu, with significant experience at retail giants like Nike and Kohl's, is taking on the role of Chief Digital and Information Officer (CDIO) at Elevance Health. This strategic move suggests a growing emphasis on technological innovation within the healthcare sector. Lavu's goal is to infuse healthcare with the same "delight" and customer-centric approach typical of retail, leveraging technology to enhance the overall patient and user experience. For investors, the arrival of an executive with such a diverse and consumer-oriented background could signal a potential acceleration in Elevance Health's digital transformation, promising greater operational efficiency and improved customer loyalty, key drivers for future growth.

  • 2/24/2026NEUTRAL
    Elevance Health Executive: Committed to Affordability

    Catherine Gaffigan, president of health solutions at Elevance Health, highlighted utilization as a key driver of rising healthcare costs. Speaking on Bloomberg's The Close, she elaborated that an aging population, coupled with higher pharmaceutical and hospital expenses, significantly contributes to this trend. These insights provide investors with an internal perspective on the structural challenges facing the healthcare sector. While Elevance Health is committed to affordability, the discussion around cost drivers underscores the complexity of the current landscape and the long-term pressures on healthcare providers and insurers. For investors, understanding these factors is crucial for assessing the sustainability of business models within the industry.

via Markets Gazette